Sorafenib is often used off-label in combination with azacitidine for relapsed/refractory or older/unfit FLT3-AML, given the lack of other good options for these patients outside of a clinical trial, and this use is supported by National Comprehensive Cancer Network guidelines based on a phase II trial of 37 evaluable patients with FLT3-AML showing an ORR of 46% with 10 CRi, six CR, and one PR83. Here, FLT3 is linked to acute myeloid leukemia.